How have the shares performed?
Kronos Bio Inc. (KRON) saw downtrend of -2.25% in the recent trading with $24.80 being its most recent. The current price level -37.38% lower than the highest price of $39.60 marked by the stock while trading over the past 52-weeks, whereas it is 26.53% higher than the lowest price of $19.60 the company dropped to over past 52-weeks. The latest news story on KRON appeared in GlobeNewswire under the title “Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day” on May-11-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -11.43% below one month high and is +26.53% above of the lowest during that time. Looking into the simple moving average, Kronos Bio Inc. (KRON)’s stock stands at a SMA-50 of $26.40 while that of 5-day is reading $25.03.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.70 for the stock.
Kronos Bio Inc. Earnings – What Happened With KRON
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Kronos Bio Inc. (KRON) last released financial results for the quarter that ended 12/30/2020, posting a surprise factor of 11.40% for net revenue.
KRON – Kronos Bio Inc. Stock Earnings Estimates
The perspective of Kronos Bio Inc. (NASDAQ:KRON)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.79 for stock’s EPS in the current quarter. 4 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.7.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 54.15 million. KRON does have institutional investors; and they hold 62.90% of the stock.
Kronos Bio Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, KRON declared 243,807 shares have been sold in 17 insider transactions over the past three months.
As on Dec 30, 2020, Omega Fund Management (US) Inc. was the top most holder in Kronos Bio Inc. (NASDAQ:KRON) with an ownership of 3.82 million shares of the company or 6.81% of the stake worth $114.05 million. The filing also reveals Capital Research Global Investors as the second largest holder in the company with a control over 6.32% of the outstanding shares. Its stake is worth $105.79 million for having 3.54 million shares in hand.
Perceptive Advisors Llc also came holding a key position in the company during the recent quarter and it now holds 4.96% of the outstanding shares. With this there are now 100 institutions which have possession in KRON’s shares.
Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.70 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Kronos Bio Inc. was 32.65 while posting a debt to equity ratio of 0.00. The count was 6.69 for long-term debt to equity ratio.